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Background and aims: Familial hypercholesterolemia (FH) is a common inherited disorder of low density
lipoprotein-cholesterol (LDL-C) metabolism. It is associated with higher risk of premature coronary heart
disease. Around 60% of patients with a clinical diagnosis of FH do not have a detectable mutation in the
genes causing FH and are most likely to have a polygenic cause for their raised LDL-C. We assessed the
degree of preclinical atherosclerosis in treated patients with monogenic FH versus polygenic
hypercholesterolemia.
Methods: FH mutation testing and genotypes of six LDL-C-associated single nucleotide polymorphisms
(SNPs) were determined using routine methods. Those with a detected mutation (monogenic) and
mutation-negative patients with LDL-C SNP score in the top two quartiles (polygenic) were recruited.
Carotid intima media thickness (IMT) was measured by B-mode ultrasound and the coronary artery
calcium (CAC) score was performed in three lipid clinics in the UK and the Netherlands.
Results: 86 patients (56 monogenic FH, 30 polygenic) with carotid IMT measurement, and 166 patients
(124 monogenic, 42 polygenic) with CAC score measurement were examined. After adjustment for age
and gender, the mean of all the carotid IMT measurements and CAC scores were signiﬁcantly greater in
the monogenic than the polygenic patients [carotid IMT mean (95% CI): 0.74 mm (0.7e0.79) vs. 0.66 mm
(0.61e0.72), p ¼ 0.038 and CAC score mean (95%): 24.5 (14.4e41.8) vs. 2.65 (0.94e7.44), p ¼ 0.0004].
Conclusions: In patients with a diagnosis of FH, those with a monogenic cause have a higher severity of
carotid and coronary preclinical atherosclerosis than those with a polygenic aetiology.
© 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Familial hypercholesterolemia (FH) is a common autosomal
dominant disorder and a well-known cause of premature coronary
heart disease (CHD) [1]. It has a frequency of 1 in 200e500 in most
European countries [2,3], and is caused by mutations in the lowenetics, The Rayne Building,
umphries).
r Ireland Ltd. This is an open accesdensity lipoprotein receptor (LDLR) gene, the gene coding for
apolipoprotein B (APOB) or the gene encoding protein convertase
subtilisin/kexin 9 (PCSK9) [4]. The clinical diagnosis of deﬁnite FH is
based on a low density lipoprotein-cholesterol (LDL-C) level
>4.9 mmol/L and the presence of tendon xanthomata, while pa-
tients with a diagnosis of possible FH do not have xanthomata but
have a family history of premature CHD and/or hypercholester-
olemia [5].
Only in 60e80% of deﬁnitive FH and in 20e30% of possible FH
cases, can a mutation be found. [6], and since possible FH cases
usually represent around two-thirds of the lipid clinic patients article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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only 40% of those with a clinical diagnosis of FH [6]. It has been
shown that a signiﬁcant proportion of the patients with a clinical
diagnosis of FH, where no mutation is found, are likely to have a
polygenic explanation for their raised LDL-C level [7,8]. A Global
Genetic Consortium meta-analysis identiﬁed multiple loci where
common variants associated with slight deviation in LDL-C levels
[9]. Based on the common LDL-C raising single nucleotide poly-
morphisms (SNPs), aweighted SNPs score has been developed [7,8].
Using this score, it appears that at least 20% of FH patients without a
mutation are likely to have a polygenic explanation for their LDL-C
level of over 4.9 mmol/L. In contrast, in individuals with a low LDL-
C SNP score, there is a possibility that there may be a yet uniden-
tiﬁed monogenic cause.
The elevated risk for CHD in FH patients with a detected mu-
tation has been convincingly conﬁrmed by Khera et al. in a
population-based analysis, which showed that patients with LDL-C
>4.9 mmol/L and no FH mutation had a 6-fold higher risk for CHD
and those with both LDL-C >4.9 mmol/L and an FH mutation had a
22-fold higher risk compared to subjects with normal LDL-C and no
mutation [10]. The Simon Broome register showed that the Stan-
dardized Mortality Ratio (SMR) for CHD in patients with a clinical
diagnosis of deﬁnite FH was higher than in patients with a possible
diagnosis of FH [SMR ¼ 2.94 (2.28e3.80) vs. 2.05 (1.45e2.82)] [11].
Since we now know that a mutation can be found in 60e80% of
deﬁnite FH patients, this means that the majority of this group had
a monogenic cause, while the detection rate in possible FH is only
20e30% and they were likely to have polygenic hypercholester-
olemia. Humphries et al. also reported a signiﬁcantly higher Odds
Ratio (OR) for having CHD in FH patients with an LDLR mutation
versus patients where no mutation was found [OR ¼ 1.84 vs. 1.00,
p ¼ 0.02] [12]. Several case control studies also reported the raised
CHD risk in monogenic FH patients compared to the patients with a
high LDL-C with no mutation found and the general population by
means of the imaging measurements such as angiography, CT scan
and carotid ultrasounds [13e15].
The European guideline for cardiovascular risk stratiﬁcation
recommends imaging techniques for intermediate and high risk
asymptomatic individuals such as patients with FH [16]. Coronary
artery calcium (CAC) score has long been recognized as a surrogate
marker for coronary atherosclerosis and a good predictor of future
cardiovascular events and all-cause mortality in asymptomatic
people [17,18]. Several clinical trials have shown that carotid IMT
changes are sensitive to changes in the LDL-C levels [19]. A raised
carotid IMT measurement is associated with increased risk of CHD
and serves as an atherosclerotic surrogate end-point for thera-
peutic interventions [20].
While raised LDL-C is a known risk factor for atherogenesis [21],
there are only limited data available to examine whether the extent
of early atherosclerosis is higher in treated monogenic FH than in
clinically diagnosed FH patients with the same level of LDL-C level
but a polygenic cause. In this study, for the ﬁrst time, we used the
genetic testing to conﬁrm the presence of the polygenic locus in
individuals with a raised LDL-C, where no FH causing mutationwas
found and we compared the degree of preclinical atherosclerosis in
these patients with monogenic FH patients.
2. Materials and methods
2.1. Subjects
Data from two outpatient lipid clinics in the UK, the Royal Free
Hospital in London and the Russells Hall Hospital in Dudley, and an
outpatient lipid clinic in the Netherlands, the Erasmus Medical
Centre in Rotterdam, were included in this study over the period2014e2016.
The following clinical diagnostic criteria for FH were used: an
LDL-C level above the 95th percentile for gender and age in com-
binationwith the presence of tendon xanthomas in the patient or in
a ﬁrst degree relative, or an LDL-C level above the 95th percentile
for gender and age in a ﬁrst degree relative, or a proven coronary
artery disease in a ﬁrst degree relative under the age of 60. No
patients had proven CHD or had any symptoms suggestive of
ischemic heart disease.
All patients with secondary causes of hypercholesterolemia
such as renal disease, liver disease and thyroid disease were
excluded from the study. All the patients with a CHD disease or any
symptoms of ischemic heart disease, renal insufﬁciency (serum
creatinine > 120 mmol/L), known contrast allergy or atrial ﬁbril-
lation were excluded from the study.
All patients had a genotyping test to conﬁrm their monogenic or
polygenic cause (see below) and they all had a CT scan to measure
coronary calcium score or a carotid ultrasound to measure carotid
intima media thickness. All patients were clinically asymptomatic,
meaning they had no cardiac symptoms or any history of CHD. The
inclusion age for the study varied from 30 to 70 years to have a
carotid ultrasound and 40 to 70 for CT scan. All patients gave
written informed consent. The ethical approval was obtained from
the relevant ethics committees (13/LLO/1334).
Data from all the monogenic patients and the patients with no
mutation and a gene score in the top two quartiles of LDL-C gene
scoring were included in the ﬁnal analysis of this study. The data
from the patients with no mutation in genotyping and a low gene
score were excluded from the analysis. The patients at the Rotter-
dam and Russells Hall hospital in the UK only underwent a CT scan
to measure the CAC score, while the patients at the Royal Free
hospital had only carotid IMTmeasurement. From a total number of
312 patients (94 patients at the Russells Hall and 97 at the Royal
Free hospital in the UK and 121 patients in the Netherlands), data
from 166 patients with a CAC score and 86 patients with a carotid
IMT measurement were included in the ﬁnal analysis.
2.2. Molecular analysis
2.2.1. FH genotyping
All participants had FH mutation testing for all 18 exons of the
LDLR gene, a fragment of exon 26 of APOB to cover the area for the
common mutation p.Arg3527Gln, and exon 7 of PCSK9 to cover
p.Asp374Tyr using direct sequencing analysis of PCR products
[22e24]. Multiplex Ligation-dependent Probe Ampliﬁcation to
detect gross deletions and insertions in LDLR, according to the
manufacturer's protocol on all samples (MRC-Holland, Amsterdam,
the Netherlands), and in silico prediction of pathogenicity of iden-
tiﬁed variants were also performed [25].
2.2.2. LDL-C gene score calculations for polygenic
hypercholesterolemia
The patients with no mutation detected in their FH genotyping
test were genotyped for six LDL-C-raising SNPs (CELSR2 (rs629301),
APOB (rs1367117), ABCG8 (rs4299376), LDLR (rs6511720), and APOE
(rs429358, and rs7412)) at the Cardiovascular Genetics Lab at UCL
in the UK. KASPar™ PCR technique (Kbiosciences, UK Hoddesdon,
Herts, UK) or TaqMan® assays (Life Technologies, Carlsbad, Cali-
fornia, US) and genotype calls for all assays was carried out using an
automated system, the results of which were checked manually by
study personnel using SNP viewer® software (Supplementary
Table 1) as previously described [7,8]. Patients were grouped into
quartiles of the gene score based on those reported by Futema et al.
for a healthy UK population. It has been estimated using probability
calculations that patients in the top three quartiles of the score have
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hypercholesterolemia [8]. Only data from patients with an LDL-C
SNP score in the top 2 quartiles were included in this study.
2.3. Biochemical markers
The lipid levels were measured based on the standard Lab
techniques [26]. The biochemistry tests were performed on the
automated Roche cobas® and Vitros® Fusion 5.1 analyser (Ortho-
Clinical Diagnostics, Rochester, NY, U.S.A.) at Royal Free Hospital
and the Russells Hall Hospital, respectively.
2.4. Carotid intima media thickness (IMT) measurement
The carotid IMT was measured in B-mode by a Philips CX50
machine equipped with a 5e10 MHz linear array probe at the Royal
Free Hospital in the UK. Measurements were done in the far wall of
the common carotid artery (in the second centimeter proximal to
the bifurcation), the bifurcation and the internal carotid artery on
both right and left arteries. Three scan angles of lateral, posterior
and anterior during diastole were used, and each segment was
measured in at least four different frames. IMT analysis was per-
formed by Philips QLAB® software after completed examination. In
the case of plaque presence, the IMT was measured away from the
plaque.
2.5. CT scan with coronary artery calciﬁcation (CAC) score
CACwasmeasured using Symbia TruePoint T6 SPECT/CT scanner
(Siemens Medical Solutions, Forchheim, Germany) and dual-source
CT scanner (ﬁrst 101 scans: Somatom deﬁnition, last 44 scans:
Somatom Deﬁnition FLASH, Siemens Medical Solutions, Forchheim,
Germany) [15] in the UK and in the Netherlands, respectively. The
CAC score measurement was done using the same standard Agat-
ston calcium scoring algorithm [27].
CT scans of the heart (from the carina to the apex of the heart)
were acquired during one inspiratory breath-hold without the use
of contrast medium. CAC was quantiﬁed using calcium scoring
software (Syngo CaScore, Siemens) and measurements were per-
formed using the standard Agatston calcium scoring algorithm [27],
which has been validated in several large studies. It has been shown
previously that in asymptomatic individuals with a CAC score <100,
the prevalence of cardiac ischemia is generally very low (<10%)
[28,29] Therefore, in our study, the participants were divided into
two groups for comparisonwith the calcium score above and below
100 Agatston units.
2.6. Statistics
Demographic and biochemical data are presented as mean with
standard deviation (SD) or number (percent). The carotid IMT and
CAC score data were not normally distributed, so log-transformed
data were used to compare the groups after adjustment for age
and gender (SPSS® version 21), and they were transformed back to
the original scale and presented as geometric means and 95%
conﬁdence intervals.
For carotid IMT, a linear regression model was used. For CAC
score, a tobit model was used due to the high frequency of zero
scores. Values were recoded to CACSþ1 to allow a censored
threshold of zero in the tobit model. In addition, CAC score was
analysed as two groups using a cut-point of 100 and an ordinal
regression mode. The proportional odds assumption of the ordinal
logistic regression model was satisﬁed by all variables (Brant test:
age c2 ¼ 3.1 p ¼ 0.38, sex c2 ¼ 3.96 p ¼ 0.27, study c2 ¼ 0.96
p ¼ 0.81, mutation status c2 ¼ 0.47 p ¼ 0.93).Logistic regressionwas used to adjust for age and gender for this
analysis. Mutation, centre and gender were included as dummy
variables in each model. The characteristics between the patient
groups were compared using unpaired t-tests for continuous vari-
ables and Chi-squared tests for categorical data.
Linear regression and tobit regression models were also ﬁtted
using age, mutation and an age*mutation interaction term to
determine differences between the increase in carotid IMT and CAC
score with age, in monogenic and polygenic groups, respectively.
Results are presented as beta coefﬁcient (B) and standard error (SE).
Based on the carotid IMT data in Jarauta et al. [30], a sample of 50 in
each monogenic and polygenic group would give 80% power at the
5% signiﬁcance level to detect an 11% difference in carotid IMT.
3. Results
3.1. Patient characteristics
In total, data from 252 patients were included in the study
(Table 1). 86 patients (56 monogenic and 30 polygenic) had a ca-
rotid IMT measurement and 166 patients (124 monogenic and 42
polygenic) had a CAC score measurement. There was no signiﬁcant
difference between monogenic and polygenic groups in pre-
treatment cholesterol levels in the UK centres but the pre-
treatment LDL-C in the monogenic group was signiﬁcantly higher
in the Netherlands centre. There was no signiﬁcant difference in
other conventional cardiovascular risk factors such as smoking,
hypertension, diabetes or body mass index between groups.
3.2. Carotid intima media thickness (carotid IMT)
As shown in Table 2, the mean of all carotid IMT readings (mean
IMT) was 12% higher in monogenic than polygenic patients after
adjustment for age and gender [0.74 mm (0.7e0.79) vs. 0.66 mm
(0.61e0.72), p ¼ 0.038]. Similar differences were seen in the
different segments analysed, with those of mean bifurcation IMT
and mean internal carotid artery IMT being statistically signiﬁcant.
As expected, and as shown in Fig. 1, the carotid IMT signiﬁcantly
increased with age in both monogenic and polygenic groups
compared to the general population. The increase was borderline
signiﬁcant (p ¼ 0.057) over the age of 51 (median age) in the
monogenic group. Comparing the carotid IMT in patients<51 versus
51 years old gave a mean (SD) carotid IMT of 0.63 mm (0.15) vs.
0.88 mm (0.24) in the monogenic group (p ¼ 0.0005) and
0.60 mm(0.12) vs. 0.75 mm(0.19) in the polygenic group (p ¼ 0.01).
3.3. Coronary artery calcium (CAC) score
Data for the CAC score is shown in Table 2. The CAC score did not
differ, overall, between the UK vs. Netherlands centre (14.2 vs. 19.1,
p ¼ 0.50) and both centres showed a signiﬁcantly higher CAC score
in monogenic patients. The estimated mean (95% CI) CAC score in
all centres was 24.5 (14.4e41.8) for the monogenic group, which
was signiﬁcantly higher than 2.65 (0.94e7.44) for the polygenic
group (p ¼ 0.0004) (Table 2). The CAC score was estimated to be
9.27 (95% CI: 2.74 to 31.4) times higher in the monogenic compared
to the polygenic group after adjustment for centre, age and gender
(p ¼ 0.0004).
Fig. 2 shows the number of monogenic and polygenic patients in
each CAC score category: zero, 1e99, 100e400 and > 400. A CAC
score above 100 occurred in 51 (41.1%) monogenic patients
compared to 12 (28.6%) polygenic patients with an odd ratio of 1.38
(p ¼ 0.43). After adjustment for centre, age and gender, the odds
ratio for having a CAC score >100 increased to 4.79 (95% CI:
1.67e13.75, p ¼ 0.004). A CAC score of zero was reported in 33
Table 1
Characteristics of the subjects studied.
Characteristics of patients with carotid IMT measured
Monogenic (N ¼ 56) Polygenic (N ¼ 30) p
Male N (%) 22 (40) 14 (47) 0.3
Age (years) Mean (SD) 50 (14) 57 (12) 0.03
Pre-treatment lipid levels
TC (mmol/L) Mean (SD) 8.1 (1.5) 8.2 (1.0) 0.5
LDL-C (mmol/L) Mean (SD) 5.8 (1.6) 5.9 (0.9) 0.8
HDL-C (mmol/L) Mean (SD) 1.5 (0.4) 1.9 (1.1) 0.1
TG (mmol/L) Mean (SD) 1.2 (0.5) 1.6 (0.7) 0.01
Tendon xanthoma N (%) 29 (51.7) 10 (33.3) 0.10
Family history of premature CHDa N (%) 30 (53.5) 20 (66.6) 0.24
BMI (kg/m2) Mean (SD) 26.1 (4.6) 26.4 (4.4) 0.1
Patients with hypertension N (%) 4 (7.1) 1 (3.3) 0.1
Patients with diabetes N (%) 0 (0) 1 (3.3) 0.3
Smoker N (%) 0(0) 0(0)
Post-treatment lipid levels
TC (mmol/L) Mean (SD) 4.8 (0.8) 5.0 (0.9) 0.3
LDL-C (mmol/L) Mean (SD) 2.9 (0.8) 2.8 (0.8) 0.8
HDL-C (mmol/L) Mean (SD) 1.5 (0.3) 1.6 (0.4) 0.2
TG (mmol/L) Mean (SD) 0.8 (0.2) 1.3 (0.6) 0.001
Patients on lipid lowering medication N (%) 42 (75) 25 (85) 0.7
Years treated with statin Mean (SD) 10 8 0.2
Characteristics of patients with CAC score measured UK data
Monogenic (N ¼ 49) Polygenic (N ¼ 30) p
Male N (%) 22 (44.9) 12 (40) 0.67
Age (years) Mean (SD) 43.6 (9.8) 59.6 (8.1) 0.001
Pre-treatment lipid levels
TC (mmol/L) Mean (SD) 8.6 (0.8) 8.8 (1.3) 0.76
LDL-C (mmol/L) Mean (SD) 6.3 (0.7) 6.1 (1.1) 0.66
HDL-C (mmol/L) Mean (SD) 1.5 (0.4) 1.7 (0.5) 0.3
TG (mmol/L) Mean (SD) 1.8 (0.8) 2.3 (1.2) 0.32
Tendon xanthoma N (%) 30 (61.2) 3(10) <0.001
Family history of premature CHDa N (%) 30 (61.2) 15 (50) 0.03
BMI (kg/cm2) Mean (SD) 27.7 (4.4) 29.7 (9.2) 0.58
Patients with hypertension N (%) 1 (14) 12 (40) 0.3
Patients with diabetes N (%) 0 (0) 3 (10) 0.9
Smoker N (%) 1 (14.3) 4 (13.0) 1.0
Patients on lipid lowering medication N (%) 75 (100) 23 (76) 0.1
Years treated with statin Mean (SD) 9.0 (7.5) 3.0 (3.0) 0.006
Characteristics of patients with CAC score measured Rotterdam data
Monogenic (N ¼ 75) Polygenic (N ¼ 12) p
Male N (%) 52 (69.3) 8 (66.7) 0.85
Age (years) Mean (SD) 51.4 (7.7) 55.8 (8.6) 0.07
Pre-treatment lipid levels
TC (mmol/L) Mean (SD) 9.92 (2.29) 8.72 (2.00) 0.09
LDL-c (mmol/L) Mean (SD) 7.64 (2.12) 6.22 (1.76) 0.03
Tendon xanthoma N (%) 28 (37.3) 0 e
Family history of premature
CHDa
N (%) 36 (48) 7 (58.3) 0.50
BMI (kg/cm2) Mean (SD) 26.7 (3.8) 24.6 (3.2) 0.07
Patients with hypertension N (%) 15 (20.0) 5 (41.7) 0.1
Patients with diabetes N (%) 2.7 (2) 8.3 (1) 0.36
Smoker N (%) 14 (18.7) 3 (25.0) 0.7
Post-treatment lipid levels
TC (mmol/L) Mean (SD) 5.50 (1.48) 5.27 (1.79) 0.62
LDL-C (mmol/L) Mean (SD) 3.55 (1.31) 2.89 (1.34) 0.11
HDL-C (mmol/L) Mean (SD) 1.33 (0.39) 1.37 (0.38) 0.7
TG (mmol/L) Mean (SD) 1.22 (0.87) 2.14 (3.58) 0.06
Patients on lipid lowering medication N (%) 75 (100) 11 (91.7%) 0.14
Years treated with statin Mean (SD) 10.8 (7.6) 5.8 (7.6) 0.04
a In 1st degree relative (<60 years old) or 2nd degree relatives (<50 years old).
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patients (age, study, gender adjusted p ¼ 0.01) and a CAC score
>400 was found in 26 (21.0%) monogenic patients in comparison to
5 (12.2%) in the polygenic group (age, study, gender adjusted
p¼ 0.03). CAC score datawas also available for 49 excluded subjects
with an LDL-C SNP score below our recruitment cut-off. As shown
in Supplementary Table 2, post-hoc analysis suggests that thosewith no detectable mutation and a low LDL-SNP score have a CAC
distribution that is more similar to the polygenic subjects than the
monogenic patients.
4. Discussion
Our study showed that residual preclinical atherosclerosis, as
Table 2
The mean and max carotid IMT in each carotid segment and the coronary artery calcium (CAC) score in monogenic and polygenic groups after adjustment for age and
gender.
Carotid IMT results Monogenic
(N ¼ 56)
Polygenic
(N ¼ 30)
p
mean (95% CI) mean (95% CI)
Mean IMTa (mm) 0.74 (0.70e0.79) 0.66 (0.61e0.72) 0.03
Mean CCAb IMT (mm) 0.65 (0.61e0.68) 0.62 (0.58e0.66) 0.3
Max CCAb IMT (mm) 0.72 (0.68e0.77) 0.70 (0.64e0.76) 0.5
Mean bifurcation IMT (mm) 0.81 (0.74e0.89) 0.70 (0.62e0.79) 0.05
Max bifurcation IMT (mm) 0.96 (0.85e1.07) 0.80 (0.69e0.93) 0.08
Mean ICAc IMT (mm) 0.74 (0.66e0.83) 0.60 (0.52e0.7) 0.04
Max ICAc IMT (mm) 0.82 (0.69e0.96) 0.65 (0.52e0.81) 0.1
N(%) patients with carotid plaque 12 (21%) 4 (13%) 0.4
CAC score results
(N for monogenic/N for polygenic)
Monogenic
(N ¼ 124)
Polygenic
(N ¼ 42)
p
mean (95% CI) mean (95% CI)
UK centre (49/30) 33.45 (13.9e81.5) 1.05 (0.32e3.44)
Netherlands centre (75/12) 22.9 (12.1e43.4) 11.1 (2.3e54.0)
Total 24.5 (14.4e41.8) 2.65 (0.94e7.44) 0.0004
CI, conﬁdence interval.
a Mean IMT, mean of all carotid IMT readings.
b CCA, common carotid artery.
c ICA, internal carotid artery.
Fig. 1. Mean carotid IMT measurements against age in treated monogenic FH, poly-
genic hypercholesterolemia, and the general population a.
a Scattergram of measures of mean carotid IMT in monogenic and polygenic subjects
by the age at recruitment of the subjects. General population data obtained from Stein
et al. The coefﬁcient of determination (r2) between age and IMT values is the pro-
portion of the variance in carotid IMT that can be explained by differences in age (r2 for
mutation positive ¼ 0.27, r2 for mutation negative ¼ 0.08 and r2 for general
population ¼ 0.22). The value of 0.27 for mutation positive indicates that 27% of the
variability in IMT can be explained by age variations, with 73% of the variability
unexplained.
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Fig. 2. Percentage of monogenic and polygenic patients in each CAC score category a.
a The percentage of monogenic patients and polygenic patients within each CAC score
category was estimated.
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asymptomatic monogenic FH patients compared to individuals
with a polygenic aetiology.
Lipid-lowering therapy has showed an improved clinical
outcome in patients with CHD both in primary and secondaryprevention [31]. In our study, despite the longer lipid-lowering
therapy for primary prevention in the monogenic group, both the
carotid IMT and the CAC score remained signiﬁcantly raised
compared to the polygenic group. We also found a signiﬁcantly
higher number of monogenic patients with CAC score >400, while
there was no signiﬁcant difference in other cardiovascular risk
factors among the groups. It would appear that the aetiology for
raised LDL-C in these patients play a role in determining the degree
of preclinical atherosclerosis. This could be explained by the sub-
stantially higher accumulated ‘LDL-C burden’ in monogenic pa-
tients since these patients have had genetically-determined
lifelong high LDL-C [32]. In comparison, the LDL-C level in patients
with polygenic hypercholesterolemia may only reach the LDL-C
threshold of monogenic FH patients later in life after exposure to
environmental factors (Humphries and Futema et al. unpublished).
The CAC score of zero has been reported in a range of 40e60% in
the general population, in previous population-based studies
[33,34]. In our study, we found zero calcium score in 26.6% of pa-
tients with monogenic FH patients, which was signiﬁcantly lower
than the polygenic patients (38.1%) and the general population.
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atherosclerosis, but a previous study of FH patients showed the
presence of non-calciﬁed plaque only in 4% of FH patients with zero
CAC score, and they all had less than 50% luminal obstruction [35].
Carotid IMT has been shown to be thicker in children with FH
than in their unaffected siblings [36], and in adults with a known
FH causing-mutation compared to the general population [37,38],
or patients with familial combined hypercholesterolemia [39]. Our
results show that in treated monogenic patients, carotid IMT re-
mains raised compared to treated polygenic patients and the gen-
eral population throughout adulthood, although there was no
signiﬁcant difference in the percentage of patients with carotid
plaque. This result should be viewed with caution since it is based
on cross-sectional data, and validation of this using multiple
measures is required. A total sample size of around 600 would be
required to detect a signiﬁcant (80% power at p ¼ 0.05) interaction
effect between age and carotid IMT thickness, comparing mono-
genic with polygenic subjects.
In all three groups, the monogenic subjects were younger and
had been treated with statins for longer than the polygenic pa-
tients. While there is some evidence that statin treatment itself
may be associated with high levels of coronary calcium (possibly as
the plaque becomes lipid depleted and more stable) [40], we
believe it is unlikely that differences in lipid-lowering treatment in
the two groups explain the differences seen here.
The principle limitation of this study is the relatively small
sample size. However, a strength of our study is that, in patients
with a clinical diagnosis of FH, two different measures of athero-
sclerosis burden (carotid IMT and CAC score), in three completely
independent centres, consistently found a lower burden in patients
with a polygenic compared to a monogenic aetiology. Although all
subjects fulﬁlled the clinical diagnosis of FH, it is possible that a
small proportion of those designated as “polygenic” may carry an
FH-causing mutation in the LDLR/APOB/PCSK9 genes that has been
missed because of technical reasons in the methods used for mu-
tation detection, although this is unlikely to be more than 1e2 for
each of the study groups. The inclusion of a few monogenic FH
patients in the polygenic group would mean that the measured
mean levels of carotid IMT or CAC score would be higher than that
in a “pure” polygenic group, and as such could not be a confounder
of the differences seen here. Conversely, since all the identiﬁed
mutations in this group have been previously reported as FH-
causing, there is likely to be no inclusion of any “false-positive”
cases in the monogenic group.
Clearly, the differences in carotid IMT and coronary calciﬁcation
seen here should be conﬁrmed in a larger sample, and further
studies of the coronary atherosclerosis burden would strengthen
the inference. If it is conﬁrmed that monogenic FH patients have
higher residual atherosclerosis than polygenic ones, then it would
be essential to have a better screening programme for FH patients.
The availability of next generation sequencing for genetic screening
and the non-invasive imaging techniques in clinical settings would
help clinicians to prioritize the candidates with monogenic FH for
better cardiovascular risk stratiﬁcation and appropriate utilisation
of funds in health services (e.g., use of novel therapeutic agents,
such as PCSK9 monoclonal inhibitors).
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